- Company
- "AI pathology analysis changes trt paradigm…Lunit presents"
- by Hwang, byoung woo Oct 23, 2025 06:11am
- At the European Society for Medical Oncology conference (ESMO Congress 2025), Lunit presented new clinical evidence for its Artificial Intelligence (AI) pathology analysis. The results are particularly significant as Lunit demonstrated that AI can distinguish treatment response in a subset of proficient mismatch repair (pMMR) colorectal cance
- Company
- Boehringer withdraws 1 lawsuit over unlisted Trajenta patent
- by Kim, Jin-Gu Oct 22, 2025 06:11am
- Boehringer Ingelheim has voluntarily withdrawn one of its ongoing patent disputes involving unlisted Trajenta (linagliptin) patents. Attention is focused on whether this withdrawal will lead to the conclusion of other ongoing disputes, as Boehringer Ingelheim has been pursuing unlisted patent challenges even after the launch of Trajenta g
- Company
- Targeting EZH1·2…Hanmi unveils next-gen anticancer agent
- by Hwang, byoung woo Oct 22, 2025 06:10am
- Hanmi Pharmaceutical has unveiled another pillar of its new anticancer pipeline at the ESMO Congress 2025 (European Society for Medical Oncology). The company presented Phase 1 clinical trial results of 'EZH1/2 dual inhibitor (HM97662),' suggesting possibilities for a new anticancer mechanism that could overcome drug resistance. DailyPharm
- Company
- ‘Age-specific vaccination needed to address unmet needs'
- by Son, Hyung Min Oct 22, 2025 06:09am
- A new vaccine targeting the largest number of serotypes in the pneumococcal market has been introduced in Korea. MSD Korea plans to address unmet needs in pneumococcal disease through age-specific prevention strategies, following the release of its adult vaccine, which follows pediatric vaccines. On the 21st, MSD Korea held a press con
- Company
- FutureChem to apply for cond approval of Ludotadipep in KOR
- by Hwang, byoung woo Oct 22, 2025 06:08am
- Results for FutureChem's next-generation radioligand therapy (RLT) ‘Ludotadipep (FC705)’, presented at the European Society for Medical Oncology (ESMO 2025), are drawing significant attention. In a multiple-dose clinical trial for patients with metastatic castration-resistant prostate cancer (mCRPC), the cumulative radiation dose to major o
- Company
- 'Will accelerate innovation through AI and clinical focus'
- by Hwang, byoung woo Oct 21, 2025 06:20am
- “AI is now at the heart of drug development. We must make our clinical support system more flexible and manage budgets more efficiently.” At the 2025 European Society for Medical Oncology (ESMO)&8212;one of the world’s largest cancer conferences&8212;Dr. Yeong-Min Park, Director of the Korea Drug Development Foundation (KDDF), stressed t
- Company
- Pluvicto demonstrates first-line efficacy in prostate cancer
- by Hwang, byoung woo Oct 21, 2025 06:19am
- Novartis’ radioligand therapy Pluvicto (lutetium vipivotide tetraxetan; [¹&8311;&8311;Lu]Lu-PSMA-617) has demonstrated a clinically meaningful benefit as first-line treatment in patients with metastatic hormone-sensitive prostate cancer (mHSPC). This is considered the first Phase III evidence confirming Pluvicto's potential to extend beyo
- Company
- Eliquis 13%, Xarelto 49% of DOAC Generics mkt
- by Kim, Jin-Gu Oct 21, 2025 06:19am
- In Korea’s direct oral anticoagulant (DOAC) market, Eliquis (apixaban) generics have regained a 13% market share within a year of re-entering the market. However, that figure remains roughly half the level prior to their withdrawal. By contrast, Xarelto (rivaroxaban) generics have continued to expand their presence, reaching a 49% market sha
- Company
- 'Rezurock' for cGVHD enters NHIS drug price negotiation
- by Eo, Yun-Ho Oct 20, 2025 06:08am
- 'Rezurock,' a treatment for the treatment of chronic graft-versus-host disease (cGVHD), has entered the last stage for insurance reimbursement listing. Sanofi Korea and the National Health Insurance Service (NHIS) are currently under negotiations for the drug pricing of the ROCK2 inhibitor 'Rezurock (belumosudil). Rezurock is a pharma
- Company
- Enhertu redefines the standard in early-stage breast cancer
- by Hwang, byoung woo Oct 20, 2025 06:08am
- The antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan, T-DXd) has taken center stage as a new cornerstone in the treatment strategy for early-stage breast cancer. Both the DESTINY-Breast05 and DESTINY-Breast11 trial results that were presented at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin showed signi
